Additionally, SpyGlass-DS introduces opportunities for increased downstream revenue associated with treatments for malignancies diagnosed during a cholangioscopy procedure. One study found that the downstream events attributable to the SpyGlass DS System yielded an overall - across both therapeutic and diagnostic uses of SpyGlass-DS - net positive impact of $2,942 over a 90-day post-procedure follow-up period (including the index cholangioscopy procedure).3
ERCP with cholangioscopy is associated with a decrease in costs compared to ERCP alone.4
To find out more about the potential economic impact of the SpyGlass DS System, contact your local Boston Scientific Field Reimbursement Manager at ENDOFRM@bsci.com.
Boston Scientific regularly collaborates with gastroenterology societies and government agencies to advocate for appropriate reimbursement and to address regional and national reimbursement challenges.
Visit our reimbursement site and find the latest SpyGlass DS System Coding Scenarios guide and other related reimbursement content.